Full Title: Study of INBRX-109 in Conventional Chondrosarcoma

Status: Active, Recruiting

Age Range: 18 years and older

Locations: Royal Marsden NHS Foundation Trust

Registry Number: NCT04950075

Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

This antibody activates the human death receptor 5 (DR5), a protein present on the surface of cancer cells. The activation of this protein leads to the death of cancer cells (apoptosis).

This study is a multinational trial recruiting in the USA, France, Germany, Ireland, Italy, the Netherlands, Spain and the UK.

Further centres in the UK are associated with this trial, although not yet recruiting - University College London, The Christie NHS Foundation Trust, Manchester and Churchill Hospital Oxford.

If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust. For more information on this trial and to understand if you are eligible, please talk to your clinical team.

Donate now (This link opens in a new window) More about Chondrosarcoma